Intensified carboplatin regimen with GM-CSF support in non-small cell lung cancer (NSCLC). A Hellenic Co-operative Oncology Group study (HeCOG)
Date
1997Author
Nikolaides, C.Klouvas, G. D.
Fountzilas, George
Athanasiades, A.
Skarlos, Dimosthenis V.
Samantas, E.
Kosmidis, Paraskevas A.
Mylonakis, N.
![ORCID logo](https://orcid.org/sites/default/files/images/orcid_16x16.png)
Source
Journal of Experimental and Clinical Cancer ResearchVolume
16Issue
1Pages
91-94Google Scholar check
Keyword(s):
Metadata
Show full item recordAbstract
This is a continuation of a HeCOG previous trial utilizing carboplatin and vindesine in conventional doses as a non-toxic regimen provided easily on an outpatient basis in NSCLC. In the present study we investigated whether an intensified dose-carboplatin could yield a better response. Carboplatin at a dose of 450 mg/m2 dose in combination with vindesine 3 mg/m2 every three weeks and GM-CSF support was used in a phase II study to treat 44 patients with non-small cell lung cancer (NSCLC). As compared to our previous study carboplatin dose intensity was increased from 75 mg/m2/wk to 150 mg/m2/wk. Six patients (13.6%) responded to treatment and all were partial responders. The median duration of response was 5 months (range 1.5-9 month). After a retrospective analysis a dose response effect was not evident at different carboplatin AUC doses. Twenty patients (45.45%) experienced thrombocytopenia and seventeen patients (38.6%) anemia as major toxicities. This study shows that in NSCLC a dose-response effect does not exist between carboplatin dose intensification and response rate cannot be traced.